Axogen Inc vs Remitly Global Inc — how do they compare? Axogen Inc trades at $48.85 (market cap $2.59B), while Remitly Global Inc trades at $23.73 (market cap $4.87B). The key difference: Remitly Global Inc is the larger of the two by market cap, and Axogen Inc is trading nearer its 52-week high, Remitly Global Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | RELY | |
|---|---|---|
Market Cap | $2.59B | $4.87B |
Sector | Technology | Technology |
52-Week High | $48.48 | $25.93 |
52-Week Low | $14.16 | $12.20 |
Enterprise Value | $2.50B | $4.23B |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
RELY stock trades at $24.42, down 5.82% over 24 hours, but maintains strong bullish technical signals with support at $24 and resistance at $26. The company demonstrates impressive fundamental momentum with Q2 2026 EPS of $0.93 beating expectations by 650% and revenue growth accelerating to 20% year-over-year. Recent initiatives include the Global Card launch and UAE licensing expansion, positioning for continued market share gains in the $800 billion remittance market.
With 92% analyst buy ratings and a $31 consensus price target implying 27% upside, RELY presents compelling growth potential. Key risks include execution challenges in new product launches and competitive pressure in digital payments. The stock's valuation at 17.56x P/E appears reasonable given 32.25% ROE and projected 16.85% net margins for 2026.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →